La dolce vita: fueling chimeric antigen receptor (CAR) T cells with Glut1 to improve therapeutic efficacy.

The approval of chimeric antigen receptor (CAR) T cell therapies for the treatment of hematological cancers has marked a new era in cancer care, with seven products being FDA approved since 2017. However, challenges remain, and while profound effects are observed initially in myeloma, the majority of patients relapse, which is concomitant with poor CAR T cell persistence. Similarly, the efficacy of CAR T cell therapy is limited in solid tumors, largely due to tumor antigen heterogeneity, immune evasion mechanisms, and poor infiltration and persistence.

Enhancing Sensitivity of Point-of-Care Thyroid Diagnosis via Computational Analysis of Lateral Flow Assay Images Using Novel Textural Features and Hybrid-AI Models.

Lateral flow assays are widely used in point-of-care diagnostics but face challenges in sensitivity and accuracy when detecting low analyte concentrations, such as thyroid-stimulating hormone biomarkers. This study aims to enhance assay performance by leveraging textural features and hybrid artificial intelligence models. A modified Gray-Level Co-occurrence Matrix, termed the Averaged Horizontal Multiple Offsets Gray-Level Co-occurrence Matrix, was utilised to compute the textural features of the biosensor assay images.

Off-the-shelf allogeneic natural killer cells for the treatment of COVID-19.

Low levels and function of natural killer (NK) cells are associated with increased coronavirus disease 2019 (COVID-19) severity. NK cell immunotherapy may improve immune function to reduce infection severity. We conducted a first-in-human, open-label, phase 1, dose-escalating (100 × 10, 300 × 10, or 900 × 10 cells) study of a single dose of DVX201, a cord-blood-derived allogeneic NK cell therapy, in hospitalized patients with COVID-19.